On Friday, the U.S. Supreme Court granted certiorari to a petition filed by patent owner Hikma Pharmaceuticals, taking up ...
Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group and a long-standing Health Industry Partner ...
Hikma Pharmaceuticals USA will invest $1 billion by 2030 to further expand its U.S. manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines ...
Margin outlook for injectables unit lowered Overall 2025 forecasts maintained, including tariff impact First-half profit dips, but not as bad as analyst expectations Aug 7 (Reuters) - Hikma (HIK.L), ...
The Jordan Times on MSN
Queen Rania visits Hikma Pharmaceuticals in Al Salt
AMMAN — Her Majesty Queen Rania visited Hikma Pharmaceuticals’ site in Al Salt on Monday, where she met with a number of its employees and learned more about the company’s initiatives in women ...
Thank you, everyone, for joining our 2025 half year results presentation. I'm Riad Mishlawi, CEO of Hikma, and I am joined here by Khalid Nabilsi, our CFO. Let me start by saying how pleased I am with ...
Hikma is introducing the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name Tyzavan. “The approval of Tyzavan underscores our team’s exceptional R&D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results